You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Corcept Therapeutics Inc reported third-quarter revenue of $340.5 million, up 33%, and net income of $126.8 million; it reiterated 2026 revenue guidance of $1.1 to $1.2 billion and awaits an FDA decision on Rellichloralant by its December 17th PDUFA date.
Corcept Therapeutics Incorporated announced Sean Maduck’s resignation as President of Endocrinology effective October 1, 2026, with Justin Gunn succeeding him. Maduck will consult through September 30, 2027, at $57,000 per month, while his outstanding options continue vesting.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Third-quarter revenue rose 64% to $340.5 million, net income reached $126.8 million, cash and investments increased to $662.3 million, and guidance was reiterated as both businesses continued growing; Lifyorli adoption remained rapid and broad. BELLA, DAZALS, and MONARCH reported favorable results, CHMP recommended European approval, and major trials are expected to generate data in 2027, but operating expenses increased and the Cushing syndrome NDA decision remains pending after a prior complete response letter.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Average Price Paid Per Share | $109.75 | three months ended September 30, 2026 filing | — |
| Average Price Per Share | $111.41 | three months ended September 30, 2026 filing | — |
| Dollar Amount of Shares That May Yet be Purchased Under the Program | 5.68M | three months ended September 30, 2026 filing | — |
| Total Number of Shares Purchased | 556K | three months ended September 30, 2026 filing | — |
| Total Number of Shares Repurchased | 52K | three months ended September 30, 2026 filing | — |
| Total Purchase Price of Shares | 61.95M | three months ended September 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CORT
this stock
Corcept Therapeutics Inc
|
$7.98B | +109.6% | +12.8% | 57.4 | 8.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CORT | +0.2% | -33.8% | +20.8% | -10.1% | +109.6% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -2.4% | -32.6% | +20.3% | -9.9% | +99.0% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
